Advertisement

Magen-Darm-Mittel und Laxantien

  • Joachim Mössner
  • Karl Hans Holtermüller

Zusammenfassung

Bedeutsamste Gruppe der Magen-Darm-Mittel sind die Protonenpumpenhemmer zur Behandlung der Refluxkrankheit und der Magen-Duodenalulzera. Zweitgrößte Gruppe sind die Laxantien, bei denen die Lactulosepräparate dominieren. Kleinere Verordnungsvolumen entfallen auf Prokinetika, Mittel gegen chronisch-entzündliche Darmkrankheiten und Virushepatitis B und C sowie Antidiarrhoika, Pankreasenzyme und Carminativa.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. Bleichner G, Blehaut H, Mentec H, Moyse D (1997): Saccharomyces boulardii prevents diarrhea in critically ill tube-fed patients. Intensive Care Med 23: 517–523.PubMedCrossRefGoogle Scholar
  2. Bombardier C, Laine L, Reicin A et al (2000): Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med 343:1520–1528.PubMedCrossRefGoogle Scholar
  3. Caspary WF, Lüpke NP, Oldiges FJ, Wähle K (1995): Diarrhoe in der ärztlichen Praxis. Münch Med Wochenschr 137:411–415.Google Scholar
  4. Cetina-Sauri G, Basto GS (1991): Antidiarrhöische Therapie bei Kindern. Der Kinderarzt 22:2059–2061.Google Scholar
  5. Chan FK, Hung LC, Suen BY, Wu JC, Lee KC, Leung VK, Hui AJ, To KF, Leung WK, Wong VW, Chung SC, Sung JJ (2002): Celecoxib versus diclofenac and omeprazole in reducing the risk of recurrent ulcer bleeding in patients with arthritis. N Engl J Med 347: 2104–2110.PubMedCrossRefGoogle Scholar
  6. Ellenrieder V, Boeck W, Richter C, Marre R, Adler G, Glasbrenner B (1999): Prevalence of resistance to Clarithromycin and its clinical impact on the efficacy of Helicobacter pylori eradication. Scand J Gastroenterol 34:750–756.PubMedCrossRefGoogle Scholar
  7. Gionchetti P, Rizzello F, Helwig U, Venturi A, Lamers KM et al (2003): Prophylaxis of pouchitis onset with probiotic therapy: a double-blind, placebo-controlled trial. Gastroenterology 124:1202–1209.PubMedCrossRefGoogle Scholar
  8. Gionchetti P, Rizzello F, Venturi A, Brigidi P, Matteuzzi D, Bazzocchi G et al (2000): Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology 119: 305–309.PubMedCrossRefGoogle Scholar
  9. Guarner F, Malagelada JR (2003): Gut flora in health and disease. Lancet 361: 512–519.PubMedCrossRefGoogle Scholar
  10. Hawkey CJ, Karrasch JA, Szczepanski L, Walter DG, Barkun A et al (1998): Omeprazole compared with misoprostol for ulcers associated with nonsteroidal anti-inflammatory drugs. Omeprazole versus Misoprostol for NSAID-induced Ulcer Management (OMNIUM) Study Group. N Engl J Med 338: 727–734.PubMedCrossRefGoogle Scholar
  11. Hellers G, Cortot A, Jewell D et al (1999): Oral budesonide for prevention of post-surgical recurrence in Crohn’s disease. Gastroenterology 116:294–300.PubMedCrossRefGoogle Scholar
  12. Höchter W, Chase D, Hagenhoff G (1990): Saccharomyces boulardii bei akuter Erwachsenendiarrhoe. Wirksamkeit und Verträglichkeit der Behandlung. Münch Med Wochenschr 132:188–192.Google Scholar
  13. Hoffmann, RM, Kruis W (2002): Probiotika und Präbiotika — eine Renaissance? Internist 43:1400–1406.PubMedCrossRefGoogle Scholar
  14. Kark W, Krebs-Richter H, Hotz J (1995): Improving the effect of orthograde colonic lavage with golytely Solution by adding dimethicone. Z Gastroenterol 33:20–23.PubMedGoogle Scholar
  15. Koletzko S (1997): Sonstige Erkrankungen des Magen-Darm-Traktes. In: Reinhardt D (Hrsg): Therapie der Krankheiten im Kindes-und Jugendalter. 6. Aufl., Springer, Berlin Heidelberg New York, S. 759–776.Google Scholar
  16. Kollaritsch H, Holst H, Grobara P, Wiedermann G (1993): Prophylaxe der Reisediarrhöe mit Saccharomyces boulardii. Fortschr Med 111:152–156.PubMedGoogle Scholar
  17. Kruis W, Schütz E, Fric P, Judmaier G, Stolte M (1997): Double-blind comparison of an oral Escherichia coli preparation and mesalazine in maintaining remission of ulcerative Colitis. Aliment Pharmacol Ther 11:853–858.PubMedCrossRefGoogle Scholar
  18. Labenz J, Tillenburg B, Peitz U, Kohl H, Becker T et al (1996): Ulcusheilung durch Helicobacter-pylori-Eradikation: Genügt eine Woche Therapie? Dtsch Med Wochenschr 121:3–8.PubMedCrossRefGoogle Scholar
  19. Lee JM, Breslin NP, Hyde DK, Buckley MJ, O’Morain CA (1999): Treatment options for Helicobacter pylori infection when proton pump inhibitor-based triple therapy fails in clinical practice. Aliment Pharmacol Ther 13:489–496.PubMedCrossRefGoogle Scholar
  20. Lind T, Mégraud F, Unge P, Bayerdörffer E, O’Morain C, Spiller R, van Zenten S et al (1999): The MACH 2 study: Role of omeprazole in eradication of Helicobacter pylori with I-week triple therapies. Gastroenterology 116: 248–253.PubMedCrossRefGoogle Scholar
  21. Lüth S, Teyssen S, Kölbel CB, Singer MV (2001): 4 day triple therapy with rabeprazole, amoxicillin and clarithromycin in the eradication of Helicobacter pylori in patients with peptic ulcer disease. Z Gastroenterol 39:279–285.PubMedCrossRefGoogle Scholar
  22. Madisch A, Melderis H, Mayr G, Sassin I, Hotz J (2001): Ein Phytotherapeutikum und seine modifizierte Rezeptur bei funktioneller Dyspepsie. Ergebnisse einer doppelblinden plazebokontrollierten Vergleichsstudie. Z Gastroenterol 39:511–517.PubMedCrossRefGoogle Scholar
  23. Malchow H A (1997): Crohn’s disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn’s disease? J Clin Gastroenteraol 25: 653–658.CrossRefGoogle Scholar
  24. Malfertheiner P, Mössner J, Fischbach W, Layer P, Leodolter A, Stolte M, Demleitner K, Fuchs W (2003): Helicobacter pylori eradication is beneficial in the treatment of functional dyspepsia. Aliment Pharmacol Ther 18:615–625.PubMedCrossRefGoogle Scholar
  25. McFarland LV, Surawicz CM, Greenberg RN (1994): A randomized placebo-controlled trial of saccharomyces boulardii in combination with Standard antibiotics for Clostridium difficile disease. JAMA 271:1913–1918.PubMedCrossRefGoogle Scholar
  26. Metcalf TJ, Irons TG, Sher LD, Young PC (1994): Simethicone in the treatment of infant colic: a randomized placebo-controlled multicenter trial. Pediatrics 94: 29–34.PubMedGoogle Scholar
  27. Peters FTM, Ganesch S, Kuipers EJ, Sluitder WJ, Klinkenberg-Knol EC, Lamers CBHW, Kleibeucker JH (1999): Endoscopic regression of Barrett’s oesophagus during omeprazole treatment; a randomised double blind study. Gut 45: 489–494PubMedCrossRefGoogle Scholar
  28. Rembacken BJ, Snelling AM, Hawkey PM, Chalmers DM, Axon ATR (1999): Non pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative Colitis: a randomised trial. Lancet 354:635–639.PubMedCrossRefGoogle Scholar
  29. Rösch W, Vinson B Sassin I (2002): A randomized clinical trial comparing the efficacy of a herbal preparation STW5 with the prokinetic drug cisapride in patients with dysmotility type of functional dyspepsia. Z Gastroenterol 40: 401–408.PubMedCrossRefGoogle Scholar
  30. Rutgeerts P, Löfberg R, Malchow H et al (1994): A comparison of budesonide with prednisolone for active Crohn’s disease. N Engl J Med 331:842–845.PubMedCrossRefGoogle Scholar
  31. Scarpignato C, Rampal P (1995): Prevention and treatment of traveler’s diarrhea: a clinical pharmacological approach. Chemotherapy 41(Suppl 1): 48–81.PubMedCrossRefGoogle Scholar
  32. Stange EF, Riemann J, von Herbay A, Lochs H, Fleig WE, Scholmerich J et al (2001): Diagnostik und Therapie der Colitis ulcerosa — Ergebnisse einer evidenzbasierten Konsensuskonferenz der Deutschen Gesellschaft für Verdauungs-und Stoffwechselkrankheiten. Z Gastroenterol 39:19–70.PubMedCrossRefGoogle Scholar
  33. Sudduth RH, DeAngelis S, Sherman KE, McNally PR (1995): The effectiveness of simethicone in improving visibility during colonoscopy when given with a sodium phosphate Solution: a double-bind randomized study. Gastrointest Endosc 42:413–415.PubMedCrossRefGoogle Scholar
  34. Talley NJ, Vakil N, Baillard ED, Fennerty BM (1999): Absence of benefit of eradicating helicobacter pylori in patients with nonulcer dyspepsia. N Engl J Med 341: 1106–1111.PubMedCrossRefGoogle Scholar
  35. Uemura N, Okamoto S, Yamamoto S, Matsumura N, Yamaguchi S, Yamakido M et al (2001): Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 345: 784–789.PubMedCrossRefGoogle Scholar
  36. Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M et al (1995): A comparison of five maintenance therapies for reflux esophagitis. New Engl J Med 333: 1106–1110.PubMedCrossRefGoogle Scholar
  37. Wolfe MM, Lichtenstein DR (1999): Gastrointestinal toxicity of nonsteroidal anti-inflammatory drugs. N Engl J Med 340:1888–1899.PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2004

Authors and Affiliations

  • Joachim Mössner
    • 1
  • Karl Hans Holtermüller
    • 2
  1. 1.Medizinische Klinik und Poliklinik II der Universität LeipzigLeipzig
  2. 2.Markus-Krankenhaus, 1. Medizinische KlinikFrankfurt am Main

Personalised recommendations